Kiniksa Pharmaceuticals International PLC (MEX:KNSAN)
MXN 754.37 (0%) Market Cap: 101.10 Bil Enterprise Value: 92.31 Bil PE Ratio: 78.85 PB Ratio: 9.12 GF Score: 50/100

Q4 2023 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript

Feb 28, 2024 / 01:30PM GMT
Operator

Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals' fourth quarter and full year 2023 earnings conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session.

(Operator Instructions) Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Rachel Frank, Head of Investor Relations. Please go ahead.

Rachel Frank
Kiniksa Pharmaceuticals Ltd. - IR

Thank you, operator. Good morning, everyone, and thank you for joining Kiniksa's call to discuss our fourth quarter and full year 2023 financial results and recent portfolio execution. A press release highlighting these results can be found in our website under the investor section. After the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction; Ross Moat, our Chief Commercial Officer, will provide an update on our ARCALYST commercial execution; John Paolini, our Chief Medical Officer, will review

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot